Press Releases Year All News202020192018201720162015 Forty Seven, Inc. to Present Preliminary Data from its Ongoing Phase 1 Clinical Trial of 5F9 in Acute Myeloid Leukemia at the 23rd Congress of the European Hematology Association (EHA) May 17, 2018 Forty Seven, Inc. to Present Clinical Data on 5F9, its First-in-Class CD47 Antibody, at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting May 16, 2018 Forty Seven, Inc. Granted Fast Track Designation for 5F9 for the Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma May 3, 2018 Forty Seven Inc. Appoints Ian T. Clark to Board of Directors April 30, 2018 Forty Seven, Inc. Appoints Ann D. Rhoads as Chief Financial Officer April 3, 2018 Forty Seven Inc. Appoints Kristine M. Ball to Board of Directors February 20, 2018 Forty Seven Inc. to Present at the 2018 BIO CEO & Investor Conference February 6, 2018 Forty Seven Inc. to Collaborate on a Novel Immuno-Oncology Combination for Leukemia and Bladder Cancer January 11, 2018 Forty Seven Inc. to Collaborate with Merck KGaA, Darmstadt, Germany, on a Novel Immuno-Oncology Combination for Ovarian Cancer January 11, 2018 Forty Seven Inc. to Present at the 36th Annual J.P. Morgan Healthcare Conference January 4, 2018 Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Displaying 11 - 20 of 20